OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis.
Ilaria MaccoraNiccolò LombardiGiada CrescioliAlessandra BettiolRoberto BonaiutiIlaria PagniniValerio ManiscalcoEdoardo MarraniMaria Vincenza MastroliaClaudia RavaldiRita ConsoliniMarco CattaliniNiccolò LombardiGabriele SimoniniPublished in: Rheumatology (Oxford, England) (2021)
Our real-life results seem to confirm the efficacy and safety profile of switching from originator of ADA and ETA to their respective BIOs also in paediatric patients with JIA.